X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (61) 61
male (59) 59
prostate cancer (48) 48
aged (46) 46
oncology (44) 44
radiotherapy (43) 43
prostatic neoplasms - radiotherapy (39) 39
radical prostatectomy (39) 39
middle aged (36) 36
prostatic neoplasms - mortality (32) 32
prostate-specific antigen - blood (30) 30
index medicus (29) 29
prostatic neoplasms - pathology (29) 29
cancer (26) 26
aged, 80 and over (24) 24
androgen antagonists - therapeutic use (24) 24
mortality (23) 23
radiation-therapy (20) 20
care and treatment (19) 19
follow-up studies (19) 19
prostatic neoplasms - blood (19) 19
radiation therapy (19) 19
risk factors (19) 19
urology & nephrology (18) 18
prostatic neoplasms - drug therapy (17) 17
prostate (16) 16
high energy physics - experiment (15) 15
survival (15) 15
experiment (14) 14
particle physics (14) 14
physics (14) 14
physics - high energy physics - experiment (14) 14
prognosis (14) 14
research (14) 14
risk assessment (14) 14
antineoplastic agents, hormonal - therapeutic use (13) 13
prostatic neoplasms - therapy (13) 13
radiology, nuclear medicine & medical imaging (13) 13
treatment outcome (13) 13
biopsy (12) 12
comorbidity (12) 12
hematology, oncology and palliative medicine (12) 12
men (12) 12
proportional hazards models (12) 12
prospective studies (12) 12
prostate-specific antigen (12) 12
hep (11) 11
radiation (11) 11
radiotherapy, conformal (11) 11
multivariate analysis (10) 10
survival analysis (10) 10
urology (10) 10
androgen deprivation therapy (9) 9
androgens (9) 9
article (9) 9
cause of death (9) 9
failure (9) 9
health aspects (9) 9
neoplasm staging (9) 9
recurrence (9) 9
time factors (9) 9
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (8) 8
adenocarcinoma - radiotherapy (8) 8
analysis (8) 8
antigen (8) 8
carcinoma (8) 8
cern lhc coll (8) 8
experimental results (8) 8
progression (8) 8
prostatectomy (8) 8
abridged index medicus (7) 7
adult (7) 7
cohort studies (7) 7
competing risk (7) 7
p p: colliding beams (7) 7
p p: scattering (7) 7
prostate - pathology (7) 7
prostatic neoplasms (7) 7
prostatic neoplasms - surgery (7) 7
radiology and nuclear medicine (7) 7
radiotherapy dosage (7) 7
randomized controlled-trial (7) 7
13000 gev-cms (6) 6
adenocarcinoma - drug therapy (6) 6
antigens (6) 6
beam radiation-therapy (6) 6
brachytherapy (6) 6
confidence intervals (6) 6
death (6) 6
deprivation (6) 6
deprivation therapy (6) 6
flutamide - therapeutic use (6) 6
high energy physics (6) 6
magnetic resonance imaging (6) 6
neoplasm grading (6) 6
radiology (6) 6
randomized-trial (6) 6
regression analysis (6) 6
risk (6) 6
suppression (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2002, Volume 20, Issue 23, pp. 4567 - 4573
Purpose: Identifying pretreatment and posttreatment predictors of time to prostate cancer-specific death (PCSD) after external-beam radiation therapy (RT) was... 
TRIALS | ONCOLOGY | MEN | DISEASE RECURRENCE | RADICAL PROSTATECTOMY | RADIOTHERAPY | FAILURE | NOMOGRAM | PROGRESSION | ANTIGEN | Disease-Free Survival | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Risk Assessment | Humans | Risk Factors | Proportional Hazards Models | Survival Analysis | Male | Treatment Outcome | Aged | Prostatic Neoplasms - mortality
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2019, Volume 37, Issue 7_suppl, pp. 4 - 4
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 6_suppl, pp. 21 - 21
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2009, Volume 75, Issue 1, pp. 10 - 15
Purpose To assess whether the risk of death is associated with the time to testosterone recovery (TTR) after radiotherapy (RT) and hormonal therapy (HT) for... 
Radiology | Hematology, Oncology and Palliative Medicine | Radiotherapy | Testosterone | Prostate cancer | RANDOMIZED-TRIAL | TIME | SUPPRESSION | RADIATION-THERAPY | CESSATION | ANDROGEN-DEPRIVATION THERAPY | ONCOLOGY | MEN | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | SERUM TESTOSTERONE | DURATION | AGONIST | Confidence Intervals | Prostatic Neoplasms - radiotherapy | Age Factors | Follow-Up Studies | Humans | Middle Aged | Male | Cause of Death | Flutamide - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Prostatic Neoplasms - blood | Testosterone - blood | Flutamide - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Risk Assessment | Comorbidity | Neoplasm Recurrence, Local | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Regression Analysis | Androgen Antagonists - therapeutic use | Radiotherapy, Conformal | Aged | Androgen Antagonists - adverse effects | Care and treatment | Health aspects | Risk factors | Cancer | Index Medicus | MORTALITY | PROSTATE | MULTIVARIATE ANALYSIS | PATIENTS | NEOPLASMS | TESTOSTERONE | RADIOLOGY AND NUCLEAR MEDICINE | DEATH | REGRESSION ANALYSIS | RADIOTHERAPY | HAZARDS
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2010, Volume 77, Issue 4, pp. 1046 - 1052
Journal Article